CAR-T cell therapy for cancer: current challenges and future directions
2025 · Signal Transduction and Targeted Therapy · 115 citations
https://doi.org/10.1038/s41392-025-02269-w
M
Marina Díaz‐Beyá
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
158
Papers
2.1K
Citations
23
h-index
36
i10-index
Marina Díaz‐Beyá is an academic researcher from Josep Carreras Leukaemia Research Institute. The author has contributed to research in topics: Acute Myeloid Leukemia Research & Chronic Myeloid Leukemia Treatments & Myeloproliferative Neoplasms: Diagnosis and Treatment. The author has an h-index of 23, co-authored 135 publications.
ORCID: 0000-0001-9624-2597Papers by this author
worksRepositioning of bromocriptine for treatment of acute myeloid leukemia
2016 · Journal of Translational Medicine · 22 citations
https://doi.org/10.1186/s12967-016-1007-5
Serotonin receptor type 1B constitutes a therapeutic target for MDS and CMML
2018 · Scientific Reports · 12 citations
https://doi.org/10.1038/s41598-018-32306-4
Outcomes and prognostic factors of adults with refractory or relapsed T‐cell acute lymphoblastic leukemia included in measurable residual disease‐oriented trials
2021 · Hematological Oncology · 11 citations
https://doi.org/10.1002/hon.2910
Hypomethylating agents for patients with <scp>VEXAS</scp> without myelodysplastic syndrome: Clinical outcome and longitudinal follow‐up of vacuolization and <scp><i>UBA1</i></scp> clonal dynamics
2025 · British Journal of Haematology · 8 citations
https://doi.org/10.1111/bjh.19953
Hypomethylating agents plus venetoclax for high-risk MDS and CMML as bridge therapy to transplant: a GESMD study
2025 · Experimental Hematology and Oncology · 3 citations
https://doi.org/10.1186/s40164-025-00652-5
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat